Core Viewpoint - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its product, Bu Xue Yi Mu Wan, to be classified as the first secondary protected traditional Chinese medicine variety, enhancing its market competitiveness in postpartum recovery medication [1]. Group 1 - The approval of Bu Xue Yi Mu Wan as a secondary protected variety strengthens the company's intellectual property protection [1]. - Bu Xue Yi Mu Wan is recognized as a national basic drug, a Class A medical insurance variety, and an exclusive product, included in various clinical application guidelines and textbooks [1]. - The product is indicated for conditions related to postpartum abdominal pain due to deficiency of both qi and blood, as well as blood stasis [1]. Group 2 - The company anticipates that this approval will positively impact its production and operations [1]. - The sales performance of the drug may be influenced by national policies and market environment changes, indicating a level of uncertainty [2].

Group 1: Profit Forecasts - Limin Co. expects a net profit of 465 million to 500 million yuan for 2025, representing a year-on-year increase of 471.55% to 514.57% [1] - Guohui Energy anticipates a net profit of 1.32 billion to 1.47 billion yuan for 2025, reflecting a decline of 50.03% to 55.13% year-on-year [2] - Jiajia Yue forecasts a net profit of 198 million to 228 million yuan for 2025, indicating a growth of 50.06% to 72.79% year-on-year [3] - Xianghe Industry projects a net profit of 120 million to 148 million yuan for 2025, with an expected increase of 59.17% to 96.31% year-on-year [4] - Aojie Technology predicts a net profit of 90 million to 120 million yuan for 2025, showing a growth of 228.34% to 337.79% year-on-year [14] - Shanghai Electric expects a net profit of 1.1 billion to 1.32 billion yuan for 2025, representing an increase of approximately 47% to 76% year-on-year [15] - Tianfu Communication anticipates a net profit of 1.881 billion to 2.15 billion yuan for 2025, reflecting a growth of 40% to 60% year-on-year [16] - Yichang Technology forecasts a net profit of 150 million to 225 million yuan for 2025, indicating a year-on-year increase of 58% to 138% [29] - Shanghai Yizhong expects a net profit of 60 million to 70 million yuan for 2025, representing a significant increase of 760.18% to 903.54% year-on-year [41] Group 2: Loss Forecasts - Kexin Electromechanical anticipates a net profit of 55 million to 70 million yuan for 2025, reflecting a decline of 58.65% to 67.51% year-on-year [11][12] - Kexin Technology expects a net loss of 900 million to 1.2 billion yuan for 2025, which is an increase in loss of 78.67% to 84% year-on-year [10] - Tianyang New Materials forecasts a net loss of 250 million to 180 million yuan for 2025, compared to a loss of 213 million yuan in the previous year [20] - Bo Rui Data anticipates a net loss of 90 million to 100 million yuan for 2025, which is an increase in loss of 15.17 million to 25.17 million yuan year-on-year [19] - Xinlian Integrated expects a net loss of 577 million yuan for 2025, which is a reduction in loss of approximately 40.02% compared to the previous year [40] - Fangshilong forecasts a net loss of 4 million to 6 million yuan for 2025 [30] Group 3: Strategic Developments - Lianlong signed a strategic framework agreement with Runyinglian to enhance the reliability and efficiency of the lubricant additive supply chain in China and the Asia-Pacific region [7] - Han Jian Heshan is planning to acquire a 52.51% stake in Liaoning Xingfu New Materials Co., Ltd., with stock suspension expected for up to 9 trading days [13] - Kai Zhong Precision plans to invest 116 million yuan in a technical transformation and expansion project to meet future capacity demands [34] - Tianfu Communication is expected to engage in clinical trials for its ABA001 injection, which has received approval from the National Medical Products Administration [17]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received approval from the National Medical Products Administration for its product, Bu Xue Yi Mu Wan, to be the first Chinese medicine classified as a secondary protected variety, enhancing its intellectual property protection and market competitiveness in postpartum recovery medication [1] Group 1 - The National Medical Products Administration published the announcement on January 20, 2026, approving Bu Xue Yi Mu Wan as the first secondary protected variety of traditional Chinese medicine [1] - Bu Xue Yi Mu Wan is recognized as a national basic drug, a Class A medical insurance product, and an exclusive product, included in various clinical application guidelines and textbooks [1] - The product is indicated for conditions related to postpartum abdominal pain due to deficiency of both qi and blood, as well as blood stasis [1] Group 2 - The approval strengthens the company's intellectual property protection for its products, which is expected to positively impact its production and operations [1] - The recognition of Bu Xue Yi Mu Wan is anticipated to enhance the company's competitiveness in the postpartum recovery medication market [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received approval from the National Medical Products Administration for its product, Bu Xue Yi Mu Wan, to be the first Chinese medicine to be classified as a secondary protected variety, enhancing the company's intellectual property protection and market competitiveness in postpartum recovery medication [1] Group 1 - The National Medical Products Administration published the announcement on January 20, 2026, approving Bu Xue Yi Mu Wan as the first secondary protected variety of traditional Chinese medicine [1] - Bu Xue Yi Mu Wan is recognized as a national basic drug, a Class A medical insurance product, and an exclusive product, and is included in several clinical application guidelines and textbooks [1] - The product is indicated for conditions related to postpartum abdominal pain due to deficiency of both qi and blood, as well as blood stasis [1] Group 2 - The approval of Bu Xue Yi Mu Wan is expected to positively impact the company's production and operations by strengthening its market position in the postpartum recovery medication sector [1]

Core Viewpoint - Qianjin Pharmaceutical (600479) has received approval from the National Medical Products Administration for its product, Bu Xue Yi Mu Wan, making it the first Chinese medicine to be classified as a secondary protected variety [1] Group 1 - The approved product, Bu Xue Yi Mu Wan, is indicated for conditions related to deficiency of both qi and blood, as well as blood stasis, particularly for postpartum abdominal pain [1]

Investment Rating - The report does not explicitly provide an investment rating for the gynecological drug industry in China. Core Insights - The biopharmaceutical industry in China is experiencing structural optimization, valuation recovery, and confidence rebuilding, particularly in the Hong Kong market, where the 18A system supports enterprise value discovery [2][3]. - Gynecological drug companies are characterized by specialized positioning and differentiated competition, focusing on areas such as traditional Chinese medicine, innovative treatments for gynecological tumors, and hormone drugs, showcasing strong professional images and commercialization capabilities [2][3]. Summary by Sections Capital Market Performance of China's Biopharmaceutical Sector - The A-share market has shifted from a focus on scale to sustainable development, while the Hong Kong market has attracted international capital through the 18A system, leading to a gradual rebuilding of long-term confidence in the biopharmaceutical sector [3][25]. - The A-share biopharmaceutical sector has seen a total fundraising amount of 787 billion yuan from January to October 2025, with a peak of 2,451 billion yuan in 2021, indicating a transition from a capital overheating phase to a rational development phase [13][18]. - In the Hong Kong market, the total fundraising amount reached 789 billion HKD from January to October 2025, with a peak of 1,833 billion HKD in 2020, reflecting a significant improvement in the financing environment [27][28]. Market Position Assessment of Chinese Gynecological Drug Companies - The competitive landscape of gynecological drug companies is marked by a focus on specialized fields such as innovative gynecological tumor drugs and hormone treatments, with companies establishing differentiated competitive advantages [40]. - Qianjin Pharmaceutical is recognized as a leading player in the gynecological drug market, with a strong market presence in oral gynecological inflammation traditional Chinese medicine [40]. - Heng Rui Pharmaceutical is noted for its robust pipeline in gynecological tumor treatments, with eight drugs in development as of 2024 [40]. - Xianju Pharmaceutical specializes in hormone treatments, with a focus on steroid drugs, establishing a strong professional image in the gynecological field [40]. Introduction to Representative Listed Chinese Gynecological Drug Companies - Qianjin Pharmaceutical has a significant market share of 25.8% in oral gynecological inflammation traditional Chinese medicine, demonstrating strong sales performance even in challenging market conditions [45]. - Heng Rui Pharmaceutical's research and development pipeline includes multiple innovative treatments for gynecological tumors, indicating a solid commitment to this therapeutic area [52][53]. - Xianju Pharmaceutical leverages its expertise in steroid drugs to maintain a competitive edge in the gynecological drug market, with a focus on cost-effective production and high-quality formulations [58][61].